Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PRAME-TCR-NK cells |
Synonyms | |
Therapy Description |
PRAME-TCR-NK cells are allogeneic natural killer cells engineered to express a T-cell receptor (TCR) targeting PRAME, which may induce anti-tumor activity against tumor cells expressing PRAME (Journal for ImmunoTherapy of Cancer 2024;12). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PRAME-TCR-NK cells | PRAME TCR/IL-15 NK cells|PRAME-TCR-NKs|SY-307 | PRAME-TCR-NK cells are allogeneic natural killer cells engineered to express a T-cell receptor (TCR) targeting PRAME, which may induce anti-tumor activity against tumor cells expressing PRAME (Journal for ImmunoTherapy of Cancer 2024;12). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06660420 | Phase I | PRAME-TCR-NK cells Cyclophosphamide + Fludarabine | Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel) | Not yet recruiting | USA | 0 |